141 related articles for article (PubMed ID: 7610936)
1. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion.
Garnero P; Gineyts E; Arbault P; Christiansen C; Delmas PD
J Bone Miner Res; 1995 Apr; 10(4):641-9. PubMed ID: 7610936
[TBL] [Abstract][Full Text] [Related]
2. Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease.
Delmas PD; Gineyts E; Bertholin A; Garnero P; Marchand F
J Bone Miner Res; 1993 May; 8(5):643-8. PubMed ID: 8511992
[TBL] [Abstract][Full Text] [Related]
3. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
4. The renal clearance of free and peptide-bound deoxypyridinoline: response to pamidronate treatment of Paget's disease.
Naylor KE; Jackson B; Eastell R
J Bone Miner Res; 2003 Apr; 18(4):658-61. PubMed ID: 12674326
[TBL] [Abstract][Full Text] [Related]
5. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease.
Garnero P; Gineyts E; Riou JP; Delmas PD
J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361
[TBL] [Abstract][Full Text] [Related]
6. Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links.
Randall AG; Kent GN; Garcia-Webb P; Bhagat CI; Pearce DJ; Gutteridge DH; Prince RL; Stewart G; Stuckey B; Will RK; Retallack RW; Price RI; Ward L
J Bone Miner Res; 1996 Aug; 11(8):1176-84. PubMed ID: 8854254
[TBL] [Abstract][Full Text] [Related]
7. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
[TBL] [Abstract][Full Text] [Related]
8. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
[TBL] [Abstract][Full Text] [Related]
9. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
Garnero P; Shih WJ; Gineyts E; Karpf DB; Delmas PD
J Clin Endocrinol Metab; 1994 Dec; 79(6):1693-700. PubMed ID: 7989477
[TBL] [Abstract][Full Text] [Related]
10. Investigation of bone disease using isomerized and racemized fragments of type I collagen.
Cloos PA; Fledelius C; Christgau S; Christiansen C; Engsig M; Delmas P; Body JJ; Garnero P
Calcif Tissue Int; 2003 Jan; 72(1):8-17. PubMed ID: 12384813
[TBL] [Abstract][Full Text] [Related]
11. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study.
Garnero P; Hausherr E; Chapuy MC; Marcelli C; Grandjean H; Muller C; Cormier C; Bréart G; Meunier PJ; Delmas PD
J Bone Miner Res; 1996 Oct; 11(10):1531-8. PubMed ID: 8889854
[TBL] [Abstract][Full Text] [Related]
12. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links.
Uebelhart D; Schlemmer A; Johansen JS; Gineyts E; Christiansen C; Delmas PD
J Clin Endocrinol Metab; 1991 Feb; 72(2):367-73. PubMed ID: 1991806
[TBL] [Abstract][Full Text] [Related]
13. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption.
Robins SP; Woitge H; Hesley R; Ju J; Seyedin S; Seibel MJ
J Bone Miner Res; 1994 Oct; 9(10):1643-9. PubMed ID: 7817812
[TBL] [Abstract][Full Text] [Related]
14. Effect of pamidronate on excretion of pyridinium crosslinks of collagen after total hip arthroplasty.
Wilkinson JM; Jackson B; Eastell R
Calcif Tissue Int; 2003 Oct; 73(4):326-31. PubMed ID: 12874697
[TBL] [Abstract][Full Text] [Related]
15. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
[TBL] [Abstract][Full Text] [Related]
16. Effects of age, menopause and osteoporosis on free, peptide-bound and total pyridinium crosslink excretion.
Del Campo MT; González-Casaus ML; Aguado P; Bernad M; Carrera F; Martínez ME
Osteoporos Int; 1999; 9(5):449-54. PubMed ID: 10550465
[TBL] [Abstract][Full Text] [Related]
17. The renal clearance of free and conjugated pyridinium cross-links of collagen.
Colwell A; Eastell R
J Bone Miner Res; 1996 Dec; 11(12):1976-80. PubMed ID: 8970901
[TBL] [Abstract][Full Text] [Related]
18. Multiple molecular forms of pyridinolines cross-links excreted in human urine evaluated by chromatographic and immunoassay methods.
Kamel S; Brazier M; Neri V; Picard C; Samson L; Desmet G; Sebert JL
J Bone Miner Res; 1995 Sep; 10(9):1385-92. PubMed ID: 7502711
[TBL] [Abstract][Full Text] [Related]
19. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis.
Seibel MJ; Cosman F; Shen V; Gordon S; Dempster DW; Ratcliffe A; Lindsay R
J Bone Miner Res; 1993 Jul; 8(7):881-9. PubMed ID: 8352070
[TBL] [Abstract][Full Text] [Related]
20. Assessment of urinary pyridinoline excretion with a specific enzyme-linked immunosorbent assay in normal adults and in metabolic bone diseases.
Arbault P; Grimaux M; Pradet V; Preaudat C; Seguin P; Delmas PD
Bone; 1995 Apr; 16(4):461-7. PubMed ID: 7605707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
